Med BioGene, a Vancouver, BC-based firm developing a test to stratify lung cancer patients, last week said that it has extended its biomarker collaboration with the University Health Network in Toronto.

The deal expands the firm's previous exclusive license and collaboration with UHN, which will provide additional gene expression-based markers for its early-stage non-small-cell lung cancer test.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.